HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alderuccio Juan Pablo, Olszewski Adam J, Evens Andrew M, Collins Graham P, Danilov Alexey V, Bower Mark, Jagadeesh Deepa, Zhu Catherine, Sperling Amy, Kim Seo-Hyun, Vaca Ryan, Wei Catherine, Sundaram Suchitra, Reddy Nishitha, Dalla Pria Alessia, D'Angelo Christopher, Farooq Umar, Bond David A, Berg Stephanie, Churnetski Michael C, Godara Amandeep, Khan Nadia, Choi Yun Kyong, Kassam Shireen, Yazdy Maryam, Rabinovich Emma, Post Frank A, Varma Gaurav, Karmali Reem, Burkart Madelyn, Martin Peter, Ren Albert, Chauhan Ayushi, Diefenbach Catherine, Straker-Edwards Allandria, Klein Andreas, Blum Kristie A, Boughan Kirsten Marie, Mian Agrima, Haverkos Bradley M, Orellana-Noia Victor M, Kenkre Vaishalee P, Zayac Adam, Maliske Seth M, Epperla Narendranath, Caimi Paolo, Smith Scott E, Kamdar Manali, Venugopal Parameswaran, Feldman Tatyana A, Rector Daniel, Smith Stephen D, Stadnik Andrzej, Portell Craig A, Lin Yong, Naik Seema, Montoto Silvia, Lossos Izidore S, Cwynarski Kate
Аннотация
Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) patients with HIV-BL treated from 2008 to 2019 aiming to identify prognostic factors and outcomes. With a median follow up of 4.5 years, the 3-year progression-free survival (PFS) and overall survival (OS) were 61% (95% confidence interval [CI] 55% to 67%) and 66% (95%CI 59% to 71%), respectively, with similar results in both countries. Patients with baseline central nervous system (CNS) involvement had shorter 3-year PFS (36%) compared to patients without CNS involvement (69%; P < .001) independent of frontline treatment. The incidence of CNS recurrence at 3 years across all treatments was 11% with a higher incidence observed after dose-adjusted infusional etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide (DA-EPOCH) (subdistribution hazard ratio: 2.52; P = .03 vs other regimens) without difference by CD4 count 100/mm3. In multivariate models, factors independently associated with inferior PFS were Eastern Cooperative Oncology Group (ECOG) performance status 2-4 (hazard ratio [HR] 1.87; P = .007), baseline CNS involvement (HR 1.70; P = .023), lactate dehydrogenase >5 upper limit of normal (HR 2.09; P < .001); and >1 extranodal sites (HR 1.58; P = .043). The same variables were significant in multivariate models for OS. Adjusting for these prognostic factors, treatment with cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate, ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) was associated with longer PFS (adjusted HR [aHR] 0.45; P = .005) and OS (aHR 0.44; P = .007). Remarkably, HIV features no longer influence prognosis in contemporaneously treated HIV-BL.